Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy with Depigmented and Polymerized Phleum Pratense Extract in Allergic Rhinoconjunctivitis and Asthma
NCT00501527Phase 2Completed
- Sponsor
- LETI Pharma
- Start
- Sep 2007
- Primary completion
- Oct 2009
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of phleum pratense allergoid in allergic rhinoconjunctivitis (ARC) and asthma (3 arms), sponsored by LETI Pharma. Primary endpoint: Symptom scores at 1 year. Started Sep 2007; status: completed.
02
Drugs
phleum pratense allergoid
03
Conditions
allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on NCT00501527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00501527.